---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003965"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:26:07.996529+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mirum announces preliminary 2023 net product sales of $178-180M; LIVMARLI sales up 89% YoY

## Summary
- Preliminary 2023 total revenue $186-188M; net product sales $178-180M.
- LIVMARLI net product sales $141-143M, ~89% YoY growth.
- Q4 2023 net product sales $69-71M (LIVMARLI $41-43M; CHOLBAM & CHENODAL ~$28M).
- FDA PDUFA for LIVMARLI in PFIC on March 13, 2024; NDA submission for CHENODAL in CTX in H1 2024.
- Appointed Eric Bjerkholt as CFO; company fully financed with strong balance sheet.

## SEC filing metadata
- accession: 0001193125-24-003965
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312524003965/0001193125-24-003965-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312524003965/d754126d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003965
- JSON: https://secwatch.observer/filing/0001193125-24-003965.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003965.txt

## Key facts
- Earnings Releases
  Mirum Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: revenue $186-188 million.
  - Period: the fiscal year ended December 31, 2023
  - Revenue: $186-188 million
  - Result: preliminary results
  source text: Report on Form 8-K. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates - $186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudited - LIVMARLI net products sales of $141-143 million expected
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312524003965/0001193125-24-003965-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.